eMedicine Specialties > Dermatology > Connective Tissue Diseases
Lupus Erythematosus, Drug-Induced
Updated: Aug 7, 2009
Introduction
Background
Lupus erythematosus (LE) is an autoimmune disease that can affect the skin, joints, heart, lungs, kidneys, and brain. Drug-induced lupus erythematosus (DILE) is a variant of autoimmune disease that resolves within days to months after withdrawal of the culprit drug in a patient with no underlying immune system dysfunction. Care must be taken to correctly diagnose the symptoms of drug-induced lupus erythematosus and differentiate it from the systemic autoimmune disease, and drug-induced lupus erythematosus should be recognized clinically and serologically for prompt intervention.
Erythematous macules and papules are seen on the face, upper chest, and arms in a photodistribution.
Drug-induced lupus erythematosus can arise months to years after exposure to drugs prescribed to treat various medical conditions (eg, antihypertensives, antibiotics, anticonvulsants). The most common drugs that cause drug-induced lupus erythematosus are hydralazine, procainamide, quinidine, isoniazid, diltiazem, and minocycline.
Although both systemic lupus erythematosus (SLE) and drug-induced lupus erythematosus are autoimmune disorders and can have similar clinical and laboratory features, research suggests different mechanistic pathways. Guidelines for diagnoses and management of SLE have been established.1 Although the pathogenesis of drug-induced lupus erythematosus is not completely understood, a genetic predisposition may play a role, as has been shown with certain drugs metabolized by acetylation, such as procainamide or hydralazine. Varying mechanisms leading to the formation of self-recognizing antibodies may explain the differential characteristics of drug effects in persons with drug-induced lupus erythematosus and lupus erythematosus. For example, whereas some drugs can cause drug-induced lupus erythematosus, others may cause a flare of preexisting SLE.
Drugs such as procainamide, chlorpromazine, and quinidine cause the production of antinuclear antibodies against the histone dimer H2A-H2B. Hydralazine forms antinuclear antibodies to H1 and the H3-H4 complex. Drugs that cause drug-induced lupus erythematosus usually take months to years before the associated symptoms occur, whereas flares of SLE due to drugs may occur within hours to days.
Drug-induced lupus erythematosus is characterized by improvement upon withdrawal of the offending drug or agent in a patient with a previously normal immune system. No specific criteria establish the diagnosis of drug-induced lupus erythematosus, and excluding underlying autoimmune disease is not a simple process. Obvious clinical or serologic evidence of drug-induced lupus erythematosus is not invariably present, even in rare cases of fatal drug-induced lupus erythematosus. Patients who have serologic and clinical findings that normally indicate SLE might actually have drug-induced lupus erythematosus. The symptoms of both drug-induced flares of SLE and drug-induced lupus erythematosus are temporally related to drug exposure, and SLE and drug-induced lupus erythematosus have similar manifestations. Thus, drug-induced lupus erythematosus is typically diagnosed by a process of elimination to rule out SLE.
Although both lupus erythematosus and drug-induced lupus erythematosus can affect multiple organ systems, including the skin, joints, kidneys, and CNS, complications of drug-induced lupus erythematosus that affect the kidneys and CNS are generally considered rare. In drug-induced lupus erythematosus induced by certain drugs, however, the rate of kidney involvement can be significant. For example, the rate of glomerulonephritis in hydralazine-induced drug-induced lupus erythematosus is 5-10%.
Penicillamine is also more likely to be associated with renal disease. Rare cases of death associated with drug-induced lupus erythematosus have been reported as a direct result of renal complications. Thus, a renal biopsy may be necessary to rule out membranous proliferative and necrotizing glomerulonephritis. Hepatic necrosis is another potential serious complication of drug-induced lupus erythematosus and has been documented in cases of minocycline-induced drug-induced lupus erythematosus.
For proper diagnosis, the following factors should be preliminarily confirmed:
- The patient has one or more clinical symptoms of SLE (eg, arthralgias, lymphadenopathy, rash, fever).
- Antinuclear antibodies are present.
- The patient had no history of SLE prior to using the culprit drug.
- The drug was taken anytime from 3 weeks to 2 years prior to the appearance of symptoms.
- Clinical improvement is rapid when the drug is discontinued, whereas antinuclear antibodies and other serologic markers slowly decrease toward more normal levels.
- Acebutolol
- Amiodarone
- Bupropion
- Captopril
- Carbamazepine
- Chlorpromazine
- Diltiazem
- Docetaxel
- Ethosuximide
- Gemfibrozil
- Glyburide
- Gold salt
- Griseofulvin
- Hydantoins
- Hydralazine
- Hydroxychloroquine
- Interferons
- Interleukins
- Isoniazid
- Leuprolide acetate
- Lithium
- Lovastatin
- Mephenytoin
- Methyldopa
- Minocycline
- Nitrofurantoin
- Olanzapine
- Ophthalmic timolol
- Oral contraceptives
- Penicillamine
- Phenytoin
- Practolol
- Procainamide
- Propylthiouracil
- Quinidine
- Reserpine
- Rifampin
- Sertraline2
- Simvastatin
- Sulfasalazine
- Tetracycline
- Ticlopidine
- Tiotropium bromide inhaler
- Trimethadione
- Tumor necrosis factor (TNF)3
- Valproate
- Voriconazole
- Cimetidine
- Hydralazine
- Hydrochlorothiazide
- Mesantoin
- P -Aminobenzoic acid (PABA)
- Penicillin
- Phenylbutazone
- Sulfonamides
- Terbinafine
Pathophysiology
Both SLE and drug-induced lupus erythematosus are autoimmune diseases that cause the immune system to manufacture autoantibodies against the patient's own tissues. Which drug characteristics cause the autoantibody formation is unclear, but several theories have been proposed.
One is that the drug serves as a substrate for myeloperoxidase, which is activated in polymorphonuclear neutrophils. This interaction causes the formation of reactive metabolites that directly affect lymphocyte function. A second theory is that with decreased T-cell methylation, an overexpression of lymphocyte function–associated antigen (LFA-1) occurs. T cells with hypomethylated DNA become autoreactive and cause antibody formation. This is the mechanism by which UV light causes flares of lupus. A third theory is that the genetic differences in an individual’s P450 system causes drugs to be metabolized differently, which results in the generation of toxic metabolites that may facilitate autoimmunity.
The medications and other exposures implicated in drug-induced lupus erythematosus and flares of SLE produce autoantibodies more often than systemic autoimmune symptoms. Despite these commonalities, research suggests that drug-induced lupus erythematosus and SLE have separate and distinct mechanistic pathways.
Molecular mimicry between antibodies directed against infectious agents (eg, bacteria, Epstein-Barr virus) and self-antigens has been implicated in SLE. These theories hold that in SLE, the immune system generates autoantibodies to foreign antigens and, in turn, these autoantibodies attack the patient's own tissues.
Autoantibodies in drug-induced lupus erythematosus are thought to be generated by a different mechanism than molecular mimicry. Metabolites of drugs that cause drug-induced lupus erythematosus are subjected to oxidative metabolism by neutrophils, creating reactive metabolites. Virtually all lupus-inducing drugs have been shown to undergo oxidative metabolism, while analogous non–lupus-inducing drugs do not undergo oxidation. The drug metabolite, in turn, is thought to trigger reactions in the thymus that prevent T cells from developing tolerance to the patient's own tissues. In a mouse model, reactive metabolites of procainamide injected into the thymus have been shown to result in lupuslike autoantibodies. Unlike in drug hypersensitivity reactions, this process takes months to years of drug exposure for symptoms to develop.
The production of autoimmune T cells is initiated in the thymus by the capacity of reactive drug metabolites to disrupt central T-cell tolerance. Both mouse model and human studies implicate thymic activity, possibly indicating the persistence of thymic activity into advanced adult life.
Predisposing factors to the development of drug-induced lupus erythematosus include a slow drug-acetylator phenotype and advancing patient age. Slower acetylation may play a role in the greater predisposition for elderly persons to develop drug-induced lupus erythematosus. Higher rates of drug-induced lupus erythematosus in elderly persons, however, is also likely due to decreased drug clearance and increased medication usage in these individuals.
Biologics such as interleukins (eg, interleukin 2), interferons (eg, alfa, gamma, beta), and TNF-alpha inhibitors are associated with musculoskeletal symptoms and antibody production suggestive of a lupuslike autoimmune disorder. In one study, approximately 14% of rheumatoid arthritis patients treated with anti–TNF-alpha developed anti-DNA antibodies, while less than 1% developed lupuslike symptoms. In another study, TNF-alpha protected against the development of lupus nephritis in a mouse model of SLE.
Comparison of Findings Between Drug-induced Lupus Erythematosus and Systemic Lupus ErythematosusOpen table in new window
Table
| Findings | SLE | Drug-induced Lupus Erythematosus |
|---|---|---|
| Clinical | Average age of onset of 20-30 y Affects blacks more than whites Female-to-male ratio of 9:1 | Average age of onset of 50-70 y Affects whites more than blacks Female-to-male ratio of 1:1 |
| Laboratory | Antihistone antibodies in 50% Anti-dsDNA present in 80% C3/C4 levels decrease Cutaneous findings in >75% Raynaud phenomenon in 50% Antinuclear antibodies in >95% | Antihistone antibodies in >95% Anti-ssDNA present Anti-dsDNA rare C3/C4 levels normal Cutaneous findings in ~25% Raynaud phenomenon in 25% Antinuclear antibodies in >95% |
| Immunofluorescence Histopathology | Direct immunofluorescence reveals granular deposition of immunoglobulin G at dermoepidermal junction Lymphohistiocytic interface dermatitis Apoptosis basal vacuolization | Same as SLE Same as SLE |
| Findings | SLE | Drug-induced Lupus Erythematosus |
|---|---|---|
| Clinical | Average age of onset of 20-30 y Affects blacks more than whites Female-to-male ratio of 9:1 | Average age of onset of 50-70 y Affects whites more than blacks Female-to-male ratio of 1:1 |
| Laboratory | Antihistone antibodies in 50% Anti-dsDNA present in 80% C3/C4 levels decrease Cutaneous findings in >75% Raynaud phenomenon in 50% Antinuclear antibodies in >95% | Antihistone antibodies in >95% Anti-ssDNA present Anti-dsDNA rare C3/C4 levels normal Cutaneous findings in ~25% Raynaud phenomenon in 25% Antinuclear antibodies in >95% |
| Immunofluorescence Histopathology | Direct immunofluorescence reveals granular deposition of immunoglobulin G at dermoepidermal junction Lymphohistiocytic interface dermatitis Apoptosis basal vacuolization | Same as SLE Same as SLE |
Frequency
United States
As many as 10% of the approximately 500,000 cases of lupus erythematosus may be drug-induced lupus erythematosus.
Mortality/Morbidity
Death from drug-induced lupus erythematosus is extremely rare and may result from renal involvement. In diagnosing drug-induced lupus erythematosus, first excluding the possibility of renal idiopathic lupus rather than drug-induced lupus erythematosus is extremely crucial.
Race
More whites than blacks develop drug-induced lupus erythematosus; more blacks than whites present with SLE.
Sex
In drug-induced lupus erythematosus, no significant statistical difference is apparent in the prevalence for males versus females. In contrast, SLE affects women with considerably higher frequency than men (female-to-male ratio of 9:1).
Age
Patients with drug-induced lupus erythematosus tend to be older (50-70 y) than those with SLE (average age 29 y at diagnosis). Elderly persons generally are more susceptible to drug-induced lupus erythematosus.
Clinical
History
- Most patients with drug-induced lupus erythematosus (DILE) have one or more clinical symptoms of systemic lupus erythematous (SLE), such as arthralgias, lymphadenopathy, rash, and fever, and have had no prior history of autoimmune disease. If a rash is present, it often manifests as a polycyclic, scaling, erythematous rash in sun-exposed areas.
- Approximately 50% of patients have constitutional symptoms of fever, weight loss, and fatigue.
- As many as 90% of patients with drug-induced lupus erythematosus have severe but usually noninflammatory joint pain; however, synovitis may be present.
- Arthralgia is often the only clinical manifestation of drug-induced lupus erythematosus.
- As many as 50% of patients with drug-induced lupus erythematosus experience muscle pain (myalgia).
- The drug was taken anytime from 3 weeks to 2 years prior to the appearance of symptoms. Importantly, note that drug-associated exacerbations of SLE and typical drug hypersensitivities can also be temporally related to drug exposure.
- Clinical improvement is usually rapid when the drug is discontinued, while antinuclear antibodies and other serologic markers slowly decrease toward more normal levels.
- Generally, the absence of CNS and renal involvement is more suggestive of drug-induced lupus erythematosus than SLE. High rates (ie, 5-10%) of glomerulonephritis; however, occur in hydralazine-induced drug-induced lupus erythematosus, and rare cases of death from renal involvement in drug-induced lupus erythematosus have been reported.
Physical
- Extracutaneous physical findings can include the following:
- Splenomegaly
- Hepatomegaly
- Inflammation of the serous membranes that surround the lungs and pleural cavity walls (pleurisy)
- Fever
- Inflammation of the fibroserous membranes that cover the heart and the initial part of the great vessels (ie, pericarditis)
- Cerebritis (rarely)
- Nephritis (rarely)
- Skin findings are apparent in approximately 25% of all patients diagnosed with drug-induced lupus erythematosus. Importantly, note that certain manifestations typical in persons with SLE are not usually observed in persons with drug-induced lupus erythematosus. Patients with drug-induced lupus erythematosus (unlike patients with SLE) typically do not have the following:
- Mucosal ulcers
- Hair loss (alopecia)
- Circular (discoid) plaques
- Photosensitivity (with the exception of thiazide-induced subacute lupuslike syndrome)
- Compared with patients who have SLE, patients with drug-induced lupus erythematosus present with a higher prevalence of the following:
- Purpura
- Erythema nodosum (painful nodules, usually on the extremities)
- Erythematous papules (typically on sun-exposed areas; see Media File 1)
Erythematous macules and papules are seen on the face, upper chest, and arms in a photodistribution.
- Lymphadenopathy or Raynaud phenomenon is present in approximately 35-50% of patients with SLE but in less than 25% of those with drug-induced lupus erythematosus.
- More than 75% of patients with SLE also have cutaneous findings, versus an average of less than 25% in patients with drug-induced lupus erythematosus. However, in both SLE and drug-induced lupus erythematosus, approximately 75% of patients have arthritis or arthralgia.
- Patients with drug-induced lupus erythematosus also occasionally exhibit skin findings that are analogous to those manifested in patients with subacute cutaneous lupus erythematosus, such as erythematous annular or scaly plaques.
Causes
Drug-induced lupus erythematosus may be induced by medications or caused by other compounds in the environment. The most common drugs that cause drug-induced lupus erythematosus are hydralazine (rate roughly 20%), procainamide (rate roughly 20%, 5-8% if taken for 1 y), quinidine, and minocycline.
- Several broad drug categories have been linked to drug-induced lupus erythematosus, including the following:
- Antiarrhythmics - Procainamide and quinidine
- Antibiotics - Minocycline and isoniazid
- Antifungals - Griseofulvin and voriconazole
- Anticonvulsants - Valproate, ethosuximide, carbamazepine, and hydantoins
- Hormonal therapy - Leuprolide acetate
- Antihypertensives - Hydralazine, methyldopa, and captopril
- Anti-inflammatories - Penicillamine and sulfasalazine
- Antipsychotics - Chlorpromazine
- Cholesterol-lowering agents - Lovastatin, simvastatin, and gemfibrozil
- Biologics - Interleukins (eg, interleukin 2), interferons (eg, alfa, beta, gamma), and tumor necrosis factor (TNF) inhibitors (eg, TNF-alpha)
- Inhalers - Tiotropium bromide inhaler
- Other drug categories - Ophthalmic timolol
- A genetic predisposition may play a role. Hydralazine-induced drug-induced lupus erythematosus has been observed with increased frequency in association with human leukocyte antigen (HLA)-DR4.
- Intrinsic genetic susceptibility may help explain why some patients experience drug-induced lupus erythematosus as a reaction to drug therapies, while others do not. For example, the rate of acetylation is genetically predetermined. In the United States, the population is almost evenly divided between those who are fast acetylators and those who are slow acetylators. Those with slow acetylation rates have a higher prevalence of drug-induced lupus erythematosus than those with faster acetylation rates. In contrast, SLE affects individuals with slow and fast acetylation rates approximately equally.
- Other causes may induce drug-induced lupus erythematosus in certain individuals for no apparent reason, such as sensitivity to the following:
- Insecticide compounds
- Certain metallic compounds
- Eosin (a fluorescent acid dye found in some lipsticks)
More on Lupus Erythematosus, Drug-Induced |
 Overview: Lupus Erythematosus, Drug-Induced |
| Differential Diagnoses & Workup: Lupus Erythematosus, Drug-Induced |
| Treatment & Medication: Lupus Erythematosus, Drug-Induced |
| Follow-up: Lupus Erythematosus, Drug-Induced |
| Multimedia: Lupus Erythematosus, Drug-Induced |
| References |
| Next Page » |
References
[Guideline] Finnish Medical Society Duodecim. Systemic lupus erythematosus (SLE). EBM Guidelines. Evidence-Based Medicine. Feb 20 2007;Wiley Interscience. John Wiley & Sons:[Full Text].
Hussain HM, Zakaria M. Drug-induced lupus secondary to sertraline. Aust N Z J Psychiatry. Dec 2008;42(12):1074-5. [Medline].
Sohl S, Renner R, Winter U, et al. [Drug-induced lupus erythematosus tumidus during treatment with adalimumab.]. Hautarzt. Feb 21 2009;[Medline].
Berning SE, Iseman MD. Rifamycin-induced lupus syndrome. Lancet. May 24 1997;349(9064):1521-2. [Medline].
Borg AA, Davis MJ, Dawes PT, Shadforth MF. Combination therapy for rheumatoid arthritis and drug-induced systemic lupus erythematosus. Clin Rheumatol. Sep 1994;13(3):522-4. [Medline].
Burlingame RW. The clinical utility of antihistone antibodies. Autoantibodies reactive with chromatin in systemic lupus erythematosus and drug-induced lupus. Clin Lab Med. Sep 1997;17(3):367-78. [Medline].
Callen JP, Hughes AP, Kulp-Shorten C. Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases. Arch Dermatol. Sep 2001;137(9):1196-8. [Medline].
Crowson AN, Magro CM. Diltiazem and subacute cutaneous lupus erythematosus-like lesions. N Engl J Med. Nov 23 1995;333(21):1429. [Medline].
Farver DK. Minocycline-induced lupus. Ann Pharmacother. Oct 1997;31(10):1160-3. [Medline].
Fritzler MJ. Drugs recently associated with lupus syndromes. Lupus. Dec 1994;3(6):455-9. [Medline].
Gordon MM, Porter DR, Capell HA. Does sulphasalazine cause drug induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years. Ann Rheum Dis. May 1999;58(5):288-90. [Medline].
Grant DM, Morike K, Eichelbaum M, Meyer UA. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest. Mar 1990;85(3):968-72. [Medline].
Gunnarsson I, Kanerud L, Pettersson E, Lundberg I, Lindblad S, Ringertz B. Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. Br J Rheumatol. Oct 1997;36(10):1089-94. [Medline].
Hess E. Drug-related lupus. N Engl J Med. Jun 2 1988;318(22):1460-2. [Medline].
Leak D. Absence of cross-reaction between lisinopril and enalapril in drug-induced lupus. Ann Pharmacother. Nov 1997;31(11):1406-7. [Medline].
McGuiness M, Frye RA, Deng JS. Atenolol-induced lupus erythematosus. J Am Acad Dermatol. Aug 1997;37(2 Pt 2):298-9. [Medline].
Miyasaka N. Drug-induced lupus. Intern Med. Jul 1996;35(7):527-8. [Medline].
Olsen NJ. Drug-induced autoimmunity. Best Pract Res Clin Rheumatol. Oct 2004;18(5):677-88. [Medline].
Pham HC, Saurat JH. Inhalation route inducing subacute cutaneous lupus erythematosus with tiotropium. Arch Dermatol. Jul 2005;141(7):911-2. [Medline].
Pramatarov KD. Drug-induced lupus erythematosus. Clin Dermatol. May-Jun 1998;16(3):367-77. [Medline].
Rich MW. Drug-induced lupus. The list of culprits grows. Postgrad Med. Sep 1996;100(3):299-302, 307-8. [Medline].
Rubin RL. Drug-induced lupus. Toxicology. Apr 15 2005;209(2):135-47. [Medline].
Rubin RL. Etiology and mechanisms of drug-induced lupus. Curr Opin Rheumatol. Sep 1999;11(5):357-63. [Medline].
Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. Feb 16 2002;359(9306):579-80. [Medline].
Shen GQ, Shoenfeld Y, Peter JB. Anti-DNA, antihistone, and antinucleosome antibodies in systemic lupus erythematosus and drug-induced lupus. Clin Rev Allergy Immunol. 1998;16(3):321-34. [Medline].
Toepfer M, Sitter T, Lochmüller H, Pongratz D, Müller-Felber W. Drug-induced systemic lupus erythematosus after 8 years of treatment with carbamazepine. Eur J Clin Pharmacol. Apr 1998;54(2):193-4. [Medline].
Further Reading
Keywords
drug-related lupus, lupuslike syndrome, lupus-like syndrome, lupus erythematosus medicamentosus, drug-induced systemic lupus erythematosus, SLE, drug-induced SLE, drug-induced systemic lupus erythematosus, renal idiopathic lupus, DILE, LE, drug-induced LE, autoimmune disease, procainamide, chlorpromazine, quinidine, acebutolol, amiodarone, bupropion, captopril, carbamazepine, chlorpromazine, diltiazem, docetaxel, ethosuximide, gemfibrozil, glyburide, gold salt, griseofulvin, hydantoins, hydralazine, hydroxychloroquine, interferons
interleukins, isoniazid, leuprolide acetate, lithium, lovastatin, mephenytoin, methyldopa, minocycline, nitrofurantoin, olanzapine, ophthalmic timolol, oral contraceptives, penicillamine, phenytoin, practolol, procainamide, propylthiouracil, quinidine, reserpine, rifampin, simvastatin, sulfasalazine, tetracycline, ticlopidine, tiotropium bromide inhaler, trimethadione, tumor necrosis factor, valproate, voriconazole, cimedtidine, hydralazine, hydrochlorothiazide, mesantoin, PABA, penicillin, phenylbutazone, sulfonamides, terbinafine, arthralgia, treatment, diagnosis
